small molecule. big impact.

toward safer IBD therapies

Treatment-associated side effects have a significant impact on quality of life and treatment adherence. In the context of a life-long medical condition such as IBD, addressing potential tolerability issues becomes even more critical.

Mission

improve IBD drug tolerability

giiant pharma develops gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of inflammatory bowel diseases (IBD). Precision Delivery remains central for the development of new drug therapeutics, with limited systemic exposure for safer profile and maximal local action to improve IBD patient care.

Technology

orally-delivered | gut-restricted

giiant pharma, the GastroIntestinal-Induced ANTi-inflammatory technology, is a unique targeted delivery strategy, developed by two former Merck Frosst scientists, using the bacterial activity of the gut microbiota to bioactivate and release the active drug substance at specific locations of the lower GI tract.

Although orally-delivered, giiant’s drug candidates are not systemically absorbed while still achieving high drug concentration in the colonic area.

Vision

high precision
colonic delivery

giiant pharma aims to become a GI leader in precision delivery technologies, with the ability to develop safer, patient-tailored drug therapeutcs with local tissue-specific delivery or bioactivation. These efforts should provide optimal treatment modalities to patients for various GI diseases and conditions.

Be a part of the revolution